Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
A third of patients treated with Opdivo plus Yervoy experienced complete or partial tumor remission.
A triple regimen of Opdivo, Yervoy and Cabometyx showed good activity, but side effects may limit its use.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
Opdivo plus Yervoy led to higher response rates and longer survival than Opdivo alone.
Keytruda showed modest benefits for people with hepatocellular carcinoma, and combining Opdivo with Yervoy improved outcomes.
A third of patients taking neoadjuvant Opdivo had complete responses in an early analysis.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.